New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis [Corrigendum]
Frati F, Cecchi L, Scala E, Ridolo E, Dell’Albani I, Makrì E, Pajno GB, Incorvaia C. Biologics: Targets and Therapy. 2014;8:221–226.On page 223, Figure 1 should be replaced with the revised version as shown below:On page 224, line 4 in the left column, "many&a...
Guardado en:
Autores principales: | Frati F, Cecchi L, Scala E, Ridolo E, Dell'Albani I, Makrì E, Pajno GB, Incorvaia C |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e08611437a334897a46acc787d6961de |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis
por: Frati F, et al.
Publicado: (2014) -
Sublingual immunotherapy increases Treg/Th17 ratio in allergic rhinitis
por: Wang Jiarong, et al.
Publicado: (2021) -
Sublingual house dust mite immunotherapy has no impact on decrease of circulating erythrocytes upon airway allergen challenge in allergic rhinitis
por: Galateja Jordakieva, et al.
Publicado: (2017) -
Preference for Immunotherapy with Tablets by People with Allergic Rhinitis
por: Tankersley M, et al.
Publicado: (2021) -
Seasonal changes in nasal cytology in mite-allergic patients
por: Gelardi M, et al.
Publicado: (2014)